Unknown

Dataset Information

0

Antibody interference and response kinetics of isatuximab plus pomalidomide and dexamethasone in multiple myeloma.

ABSTRACT:

SUBMITTER: Hulin C 

PROVIDER: S-EPMC8528829 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Antibody interference and response kinetics of isatuximab plus pomalidomide and dexamethasone in multiple myeloma.

Hulin Cyrille C   Beksac Meral M   Goodman Hugh J HJ   Spicka Ivan I   Alegre Adrian A   Prince Miles M   Campana Frank F   Finn Greg G   Le-Guennec Solenn S   Macé Sandrine S   Muccio Stéphane S   Tavernier Alexandra A   Rouchon Marie-Claude MC   Richardson Paul G PG  

Blood cancer journal 20211020 10

Similar Datasets

Unknown Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis.
| S-EPMC8018100 | biostudies-literature
Unknown Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis.
| S-EPMC7862055 | biostudies-literature
Unknown Real-world outcomes of isatuximab with pomalidomide and dexamethasone for relapsed and/or refractory multiple myeloma.
| S-EPMC12908833 | biostudies-literature
Unknown Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.
| S-EPMC5570682 | biostudies-literature
Unknown Exposure-response analyses for selection/confirmation of optimal isatuximab dosing regimen in combination with pomalidomide/dexamethasone treatment in patients with multiple myeloma.
| S-EPMC9197531 | biostudies-literature
Unknown Matching-adjusted indirect comparison of isatuximab plus carfilzomib and dexamethasone with daratumumab plus lenalidomide and dexamethasone in relapsed multiple myeloma.
| S-EPMC10134287 | biostudies-literature
Unknown Clinical Efficacy of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients.
| S-EPMC11613624 | biostudies-literature
Unknown Pomalidomide plus low-dose dexamethasone in relapsed refractory multiple myeloma after lenalidomide treatment failure.
| S-EPMC7027539 | biostudies-literature
Unknown A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma.
| S-EPMC5482100 | biostudies-literature
Unknown Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab-Refractory Multiple Myeloma Patients: A Multicenter Real-World Study.
| S-EPMC11789454 | biostudies-literature